Abstract: An image analyzer detects a lesion for each frame (tomographic image). When the lesion is detected, lesion information (detection flag, position information, and size information) is produced. An indication controller causes a mark surrounding the lesion to be displayed when it is judged that a mark display condition is satisfied, based on the lesion information or the like. The indication controller causes the mark to be deleted from a screen when detection of the lesion is continued and a mark display restriction condition is satisfied.

Abstract: An image analyzer detects a lesion for each frame (tomographic image). When the lesion is detected, lesion information (detection flag, position information, and size information) is produced. An indication controller causes a mark surrounding the lesion to be displayed when it is judged that a mark display condition is satisfied, based on the lesion information or the like. The indication controller causes the mark to be deleted from a screen when detection of the lesion is continued and a mark display restriction condition is satisfied.

Abstract: A thermoelectric material having improved thermoelectric properties and a method for producing the thermoelectric material are provided. The thermoelectric material contains (Mn1-x-yVxFey)Si? (0.012?x?0.045, 0?y?0.06, 1.7???1.8) and is produced by homogenously melting the raw materials including Mn, Si, and V mixed to a composition of the thermoelectric material, and then solidifying the melted raw materials at a cooling rate of 13 K/hour or less.

Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.

Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.

Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.

Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.

Abstract: There is provided a temperature switching compartment 3 which can switch the internal temperature thereof between a low temperature side at which a storage material is kept in cold storage and a high temperature side maintained at 50° C., to 80° C. at which cooked food is kept warm, by cooling with a cooler 17 and heating with a heater 15.

Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction rate of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction rate as that of the conventionally known gel.